{"name":"DAVA PHARMS INC","slug":"dava-pharms-inc","ticker":"","exchange":"","domain":"davapharms.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1971-01-01","label":"Pyrazinamide first approved","drug":"Pyrazinamide","drugSlug":"pyrazinamide","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pyrazinamide","genericName":"PYRAZINAMIDE","slug":"pyrazinamide","indication":"Initial treatment of active tuberculosis","status":"marketed"}]}],"pipeline":[{"name":"Pyrazinamide","genericName":"PYRAZINAMIDE","slug":"pyrazinamide","phase":"marketed","mechanism":"Cytochrome P450 3A4","indications":["Initial treatment of active tuberculosis","Treatment of drug-resistant tuberculosis","Treatment after failure with other primary drugs"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}